User Tools

Site Tools


projects:workgroups:kb-wg

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
Next revision Both sides next revision
projects:workgroups:kb-wg [2015/01/14 18:19]
rkboyce [Meetings]
projects:workgroups:kb-wg [2018/02/28 15:21]
rkboyce
Line 1: Line 1:
-====== ​Knowledgebase ​Workgroup ======+====== ​Pharmacovigilance evidence investigation ​Workgroup ​ ======
  
 <WRAP box justify round> <WRAP box justify round>
  
-**Objective:​** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://​www.ncbi.nlm.nih.gov/​pubmed/​24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. ​The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates ​numerous ​sources of evidence ​useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first release of LAERTES is schedule for April 2015+**Objective:​** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://​www.ncbi.nlm.nih.gov/​pubmed/​24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. ​In 2015/16 the WG contributed ​LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates ​several ​sources of evidence investigating the association of drugs and health into a single system. The first staging ​release of LAERTES ​occurred last year and is reported in https://​jbiomedsem.biomedcentral.com/​articles/​10.1186/​s13326-017-0115-3. ​
  
-**Project Lead:**  [[http://ohdsi.org/who-we-are/collaborators/​richard-d-boyce-2/​|Richard DBoyce, PhD]]+One of the primary use cases for the WG has been the creation of negative controls. Members of the WG published a paper reporting on the accuracy of automated negative control generation using machine learning and the merged evidence base: http://dx.doi.org/10.1016/j.jbi.2016.12.005 
  
-**Project Co-Lead:** [[http://ohdsi.org/who-we-are/​collaborators/​1045-2/​|Patrick Ryan, PhD]]+The current efforts of the WG are focused on improving the process of creating and maintaining the merged evidence base, providing better support in OHDSI tools for negative control generation, and developing user friendly methods for using the merged evidence base to investigate pharmacovigilance signals. Other use cases are also being discussed. The new merged evidence base is called the Common Evidence Model and is accessible by requesting data from the project leads. The WG plans to make the data accessible from the OHDSI Web API by April 2018 (see https://goo.gl/1m6NcB).  ​
  
-**Members:**+**Project Lead:** [[http://​ohdsi.org/​who-we-are/​collaborators/​erica-voss/​|Erica Voss, MPH]]
  
-See [[kb-wg#internal|Members List]]+**Project Co-Lead:​**  ​[[http://​ohdsi.org/​who-we-are/​collaborators/​richard-d-boyce-2/|Richard D. Boyce, PhD]]
  
-**Start Date:** 6/10/2014 
  
-**Repository:**  ​[[https://​github.com/​OHDSI/​KnowledgeBase]]+**Members:**
  
-**WG Minutes:** [[https://​docs.google.com/​document/​d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?​usp=drive_web|Knowledge Base WG Minutes]]+**Start Date:** 6/10/2014
  
-**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172|Knowledge Base WG Agendas]]+**Repository:**  [[https://github.com/OHDSI/CommonEvidenceModel]]
  
-</WRAP>+**WG Minutes:** [[https://​docs.google.com/​document/​d/​1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/​edit?​usp=drive_web|WG Minutes]]
  
-==== Meetings ====+**WG Agendas:** [[http://​forums.ohdsi.org/​t/​laertes-team-meeting-agenda/​172| WG Agendas]]
  
-    ScheduleEvery other Wednesday at 12 Eastern starting from January 14th 2015 +**Publications:** 
-    ​Please join my meeting. +E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics,​ Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005.  ​
-    https://global.gotomeeting.com/join/530277469+
  
-    You can call in for audio: +Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES)an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/​s13326-017-0115-3. Available athttps://​jbiomedsem.biomedcentral.com/​articles/​10.1186/​s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176. ​
-    Dial +1 (646749-3122 +
-    Access Code530-277-469+
  
-=== Minutes ​and Agendas ===+Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/​s40264-014-0189-0,​ PubMed PMID: 24985530. PMCID: PMC4134480. http://​link.springer.com/​article/​10.1007%2Fs40264-014-0189-0
  
-**WG Minutes:** [[https://​docs.google.com/​document/​d/​1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/​edit?​usp=drive_web|Knowledge Base WG Minutes]] 
  
-**WG Agendas:** [[https://​docs.google.com/​document/​d/​1AZF_nSIY4bwT_bBFPpdDObRzAUVW--Ko4S5HLJ63_y8/​edit?​usp=drive_web|Knowledge Base WG Agendas]] 
  
 +</​WRAP>​
  
-=== Discussions ​===+==== Meetings (Telecon Info) ====
  
-[[http://​forums.ohdsi.org/​t/​laertes-api/​128|Laertes API]]+    Schedule 
 +     
 +    ​All team call once per month on the 4th Wednesday of each month at 9-10 Eastern. ​
  
-[[http://​forums.ohdsi.org/​t/​laertes-update-of-the-pharmacovigilance-signals/​173/​1|update of the pharmacovigilance signals]]+    ​Touch point call on the 2nd Wednesday ​of each month 9-10 Eastern
  
-[[http://​forums.ohdsi.org/​t/​laertes-pre-load-queries-hoi-from-x-to-snomed-rxnorm-bd-to-cd/​180|LAERTES:​ pre-load queries - hoi from X to snomed, rxnorm BD to CD]] 
  
-[[http://forums.ohdsi.org/t/laertes-getting-the-pivot-correct-rolling-up-from-clinical-drug-to-ingredient/​181|LAERTES:​ getting the pivot correct - ‘rolling up’ from clinical drug to ingredient]]+ ​Please join my meeting from your computer, tablet or smartphone. ​  
 + https://global.gotomeeting.com/join/530277469 ​  
  
-=== GitHub Issues ===+ You can also dial in using your phone. ​  
 + ​United States: +1 (224) 501-3217  ​
  
-{{ghissues OHDSI/​KnowledgeBase state:open}}+ ​Access Code530-277-469  ​
  
-=== Members List ===+ More phone numbers ​  
 + ​Canada:​ +1 (647) 497-9350 ​  
 + ​France:​ +33 170 950 594   
 + ​Netherlands:​ +31 207 941 377   
 + ​Sweden:​ +46 853 527 836   
 + ​Switzerland:​ +41 225 4599 78   
 + ​United Kingdom: +44 330 221 0088  ​
  
-- Abraham G. Hartzema, PhD, University of Florida, Gainesville,​ FL 
  
-- Christian Reich, MD, PhD, AstraZeneca,​ Waltham MA+=== Discussions ===
  
-- Christophe Lambert, PhD, University of New Mexico, Albuquerque,​ NM+Search for "​LAERTES"​ on [[http://​forums.ohdsi.org/​]]
  
-- Erica A. Voss, MPH, Janssen Research and Development,​ Titusville, PA +=== GitHub Issues ===
- +
-- Gianluca Trifirò, PhD, University of Messina, Messina, Italy & Erasmus University Medical Center, Rotterdam, Netherlands +
- +
-- J. Marc Overhage, MD, PhD, Siemens Healthcare, Malvern, PA+
  
-- Jon Duke, MD, Regenstrief Institute, Indianapolis IN+[[https://​github.com/​OHDSI/​CommonEvidenceModel/​issues]]
  
-- Johan Ellenius, PhD, Uppsala Monitoring Centre, Uppsala, Sweden 
  
-- Lee Evans, LTS Computing LLC, Exton, PA+=== Active members List (add or delete your name if you see an omission or error) ===
  
-- Majid Rastegar-MojaradMSMayo ClinicRochesterMN+Erica A. VossJanssen Research & DevelopmentLLCTitusvilleNJ, EVoss3@its.jnj.com ​
  
-- Mark KhayterBSEphirBostonMA+Richard D. BoyceUniversity of PittsburghPittsburghPArdb20@pitt.edu ​
  
-- Martijn J. SchuemiePhDJanssen Research and Development,​ Titusville, PA+Lee EvansLTS Computing LLCWest Chester, PA, levans@ltscomputingllc.com ​
  
-- Michel DumontierPhDStanford UniversityStanfordCA+Anthony G. SenaJanssen Research & DevelopmentLLCTitusvilleNJ, asena5@its.jnj.com ​
  
-- Nicholas P. TatonettiPhDColumbia UniversityNew YorkNY+Vassilis KoutkiasInstitute of Applied BiosciencesCenter for Research & Technology HellasThermiThessaloniki,​ Greece, vkoutkias@certh.gr
  
-- Niklas NorenPhDUppsala Monitoring CentreUppsalaSweden+Pantelis NatsiavasInstitute of Applied BiosciencesCenter for Research & Technology HellasThermiThessaloniki,​ Greece, pnatsiavas@certh.gr
  
-- Rave HarpazPhDStanford ​University, ​Palo AltoCA+Manfred HaubenMD. MPHPfizer Inc, New York University ​Medical Center, ​ New YorkNYmanfred.hauben@pfizer.com ​
  
-- Vojtech HuserMD PhDNational Institutes of HealthBethesdaMD+Patrick B. RyanJanssen Research & DevelopmentLLCTitusvilleNJ, ryan@ohdsi.org ​
  
projects/workgroups/kb-wg.txt · Last modified: 2018/09/18 13:14 by ericavoss